Late-Breaking Clinical Trial Presented at the American College of Cardiology Supports Low-Dose Colchicine

PARSIPPANY, N.J.–(BUSINESS WIRE)–AGEPHA Pharma USA, LLC, is pleased to highlight clinical data that provides new information about how low-dose colchicine, 0.5 mg reduces the risk of major adverse cardiovascular events (MACE) and supports its use in the treatment of cardiovascular disease. The study titled, “Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients […]

Steve Andrzejewski

Co-Chair of the Board

Bio